CorMedix Surpasses Expectations with Q2 Earnings Surge

CorMedix (CRMD) reported a Q2 GAAP EPS of $0.28, beating expectations by $0.09. Revenue surged to $39.74 million, up from $0.8 million in the same quarter last year, primarily due to increased sales of DefenCath. Wall Street analysts forecast a 97.16% upside potential with an average price target of $19.67. The company has received a consensus recommendation rating of 2.0, indicating an "Outperform" status from brokerage firms.

CorMedix Inc. (Nasdaq: CRMD) has reported strong financial results for the second quarter of 2025, with net revenue surging to $39.7 million, up from $0.8 million in the same period last year. The company's net income for the quarter was $19.8 million, or $0.29 per share, compared to a net loss of $14.2 million, or $0.25 per share, in the second quarter of 2024. This significant improvement is primarily attributed to the increased sales of DefenCath, the company's lead product.

Operating expenses for the second quarter of 2025 were $18.3 million, up from $15.6 million in the same period last year. The increase was driven primarily by an increase in general and administrative (G&A) expenses and research and development (R&D) expenses. Selling and marketing expenses decreased by 14% to $6.4 million, reflecting the company's focus on commercializing DefenCath.

For the six months ended June 30, 2025, CorMedix reported net revenue of $78.8 million, up from $0.8 million in the same period last year. The company's net income for the first half of 2025 was $40.5 million, or $0.60 per share, compared to a net loss of $28.6 million, or $0.50 per share, in the same period in 2024.

In addition to its strong financial performance, CorMedix announced the acquisition of Melinta Therapeutics LLC, with a target closing date as early as September 1, 2025. The company believes that this acquisition will provide strategic benefits and help it achieve its long-term growth objectives.

Wall Street analysts have responded positively to CorMedix's Q2 results. The consensus recommendation rating is 2.0, indicating an "Outperform" status from brokerage firms. Analysts forecast a 97.16% upside potential with an average price target of $19.67.

CorMedix's management team will host a conference call and webcast today, August 7, 2025, at 8:30 a.m. Eastern Time, to discuss the company's recent corporate developments and financial results.

[1] https://cormedix.com/cormedix-inc-reports-second-quarter-2025-financial-results-and-provides-business-update/